News

Register Now for Open Forum 4: Key Issues in TB Drug Development


25 Apr 2010
by Working Group

Open Forum 4 Banner
Open Forum 4: Key Issues in TB Drug Development
August 18-19, 2010 | Addis Ababa, Ethiopia

REGISTER NOW FOR:
Open Forum 4: Key Issues
in TB Drug Development

August 18-19, 2010 | Addis Ababa, Ethiopia

International Conference to address regulatory challenges to
TB drug development in Africa.

Don’t miss this important two-day Open Forum on August 18-19, in Addis Ababa, Ethiopia. The conference will address key issues in TB drug development, with a special focus on regulatory affairs. This upcoming event will highlight TB drug development challenges in light of new treatment advances and feature keynote addresses from thought leaders in the field of tuberculosis.

Registration is free and open now. Click here and register today

This event marks the fourth in a series of crucial meetings designed to bring together regulators, TB drug developers, and other interested stakeholders such as TB care providers, public health policy-makers, and community advocates from both major industrialized and high-burden countries. Previous meetings in the series have been held in North America, Europe, and Asia, and have been attended by hundreds of key stakeholders in TB drug development and decision-makers in regulatory processes.

With the recent announcement of the Critical Path for New TB Regimens, this upcoming meeting is one of the first forums available to discuss the regulatory implications of a new TB drug development paradigm, particularly from an African perspective. The Forum will also include sessions on the current global TB drug development portfolio, key issues in the critical path to TB drug registration, designing pivotal trials, and conducting registration trials in high TB burden countries.

This meeting is sponsored by the TB Alliance, the Bill & Melinda Gates Foundation, the Stop TB Working Group on New TB Drugs, and Treatment Action Group (TAG).

Supported in part by unrestricted educational grants from AstraZeneca, Bayer Schering Pharma, Celgene, GlaxoSmithKline, Novartis International AG, Pfizer, sanofi-aventis, and Tibotec.

Accommodations and travel must be paid for by meeting attendees

> Download a list of local accommodations and rates [.pdf – 68k] > Download a map of the area [.pdf – 904k]

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...